Indications and uses
Dries the oozing and weeping, and temporarily relieves pain and itching of poison ivy, oak, and sumac or other skin irritations.
Dries the oozing and weeping, and temporarily relieves pain and itching of poison ivy, oak, and sumac or other skin irritations.
Adults and children 2 yr. of age and older. Shake well before using. Cleanse the skin with soap and water and let dry. Apply to the affected area using cotton or soft cloth, not more than 3 to 4 times daily as needed for comfort. Children under 2 yrs. of age. Consult a doctor before use.
Drug Facts
Calamine 8%
Pramoxine HCl 1%
Skin Protectant
External analgesic
Dries the oozing and weeping, and temporarily relieves pain and itching of poison ivy, oak, and sumac or other skin irritations.
For external use only. Use only as directed.
When using this product. Avoid contact with eyes and moucous membranes.
condition worsens. Symptoms last for more than 7days or clear up and occur again whitin a few days.
In case of accidental ingestion, seek profesional assistance or contact a Poison Control Center immediately.
Adults and children 2 yr. of age and older. Shake well before using. Cleanse the skin with soap and water and let dry. Apply to the affected area using cotton or soft cloth, not more than 3 to 4 times daily as needed for comfort.
Children under 2 yrs. of age. Consult a doctor before use.
SD Alcohol 38B 2.5%, Camphor, Diazolidinyl Urea, Fragrances, Glycerin, Hydroxypropyl Methycelulose, Methylparaben, Polysorbate 80, Propylene Glycol, Propylparaben and Purified Water.
Store at room temperature 15-30C (59-86F)
Distributed by: AmerisourceBergen
1300 Morris drive, Chesterbrook, PA 19087
1-800-662-3435
www.goodneighborpharmacy.com
Good Neighbor Pharmacy NDC 24385-072-82
Caldyphen Lotion
External Analgesic/Skin Protectant
Relieves ITCHING due to:
Poison Ivy Insect Bites
Poison Oak Minor Skin Irritations
6 FL OZS (177 ml)
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0087701552861 | GTIN-13: 0087701552861 EAN-13: 0087701552861 GTIN-12: 087701552861 UPC-A: 087701552861 GTIN storage (14 digits): 00087701552861 | L042096006-GNP-CALDYPHEN-LOTION.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f47a510b-6679-4664-b2d6-47b5c4afe7cc | Product name | 4 | 20260217 |
| 030ce964-9b2d-45aa-b5d3-f78ce03ef61c | Product name | 2 | 20250515 |
| 0306390c-dd77-4363-afe0-63c58088b2a1 | Product name | 1 | 20220120 |
| 503ea967-4b9c-48cf-9e87-c7975295849d | Product name | 2 | 20220120 |
| 190f2a5b-bbc8-65c7-fcb0-97891307b917 | Product name | 1 | 20140508 |
| 58f3f9b7-3b9b-a9c1-1c9f-18ac777192b8 | Product name | 1 | 20140508 |
| a7051cba-790b-a699-81f8-dbbbdbd9b5ac | Product name | 1 | 20140508 |
| da108d9e-edc8-17a3-8c28-3251c6a8accc | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 24385-072-82 | ML - Milliliter | 24385-072 | 8f13e508-d05e-4100-8b8a-4ad1b4f9f647 | 1 | 2013-07-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| PRAMOXINE HYDROCHLORIDE | ACTIVE INGREDIENT | 88AYB867L5 | 1 | |
| ZINC OXIDE | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| PRAMOXINE | ACTIVE MOIETY | 068X84E056 | 1 | |
| ZINC CATION | ACTIVE MOIETY | 13S1S8SF37 | 1 | |
| CAMPHOR (NATURAL) | INACTIVE INGREDIENT | N20HL7Q941 | 1 | |
| DIAZOLIDINYL UREA | INACTIVE INGREDIENT | H5RIZ3MPW4 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | INACTIVE INGREDIENT | R75537T0T4 | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 24385-072 | 24385-072-82 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CAMPHOR (NATURAL) | N20HL7Q941 | IACT |
| DIAZOLIDINYL UREA | H5RIZ3MPW4 | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| HYPROMELLOSE, UNSPECIFIED | 3NXW29V3WO | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| POLYSORBATE 80 | 6OZP39ZG8H | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| WATER | 059QF0KO0R | IACT |
| ZINC OXIDE | SOI2LOH54Z | ACTIM |
| PRAMOXINE HYDROCHLORIDE | 88AYB867L5 | ACTIB |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 5 | 2023-12-14 | full-release | 2026-06-01 00:04:21 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FILM COATED / ORAL | 264 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, ORALLY DISINTEGRATING / ORAL | 25 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FILM COATED / ORAL | 264 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SYRUP / ORAL | 200 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | FILM, SOLUBLE / ORAL | 201 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, ORALLY DISINTEGRATING / ORAL | 25 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | POWDER, FOR SUSPENSION / ORAL | 2940 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | GUM, CHEWING / BUCCAL | 336 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SUSPENSION / ORAL | 975 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SPRAY / NASAL | 1 mg/1ml | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, EXTENDED RELEASE / ORAL | 670 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SUSPENSION, EXTENDED RELEASE / ORAL | 727 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | LOTION / TOPICAL | 15 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | GUM, CHEWING / BUCCAL | 336 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 107 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE / ORAL | 930 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SYRUP / ORAL | 200 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE, DELAYED RELEASE / ORAL | 563 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 107 mg | ||
| DIAZOLIDINYL UREA | DIAZOLIDINYL UREA | H5RIZ3MPW4 | LOTION / TOPICAL | 3 %w/w | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | POWDER / NASAL | NA | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | FILM / SUBLINGUAL | 4.68 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SPRAY / NASAL | 1 mg/1ml | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, DELAYED RELEASE / ORAL | 103 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE, EXTENDED RELEASE / ORAL | 1508 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SUSPENSION, EXTENDED RELEASE / ORAL | 727 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE / ORAL | 930 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FOR SUSPENSION / ORAL | 76 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET / BUCCAL | 5 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, CHEWABLE / ORAL | 120 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | FILM, SOLUBLE / ORAL | 201 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, EXTENDED RELEASE / ORAL | 670 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, COATED / ORAL | 24 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SUSPENSION / ORAL | 975 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, FOR SUSPENSION / ORAL | 76 mg | ||
| DIAZOLIDINYL UREA | DIAZOLIDINYL UREA | H5RIZ3MPW4 | LOTION / TOPICAL | 3 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, COATED / ORAL | 24 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, CHEWABLE / ORAL | 120 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET / BUCCAL | 5 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | POWDER / NASAL | NA | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SPRAY, METERED / NASAL | 1 mg/1ml | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | POWDER, FOR SUSPENSION / ORAL | 2940 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | SPRAY, METERED / NASAL | 1 mg/1ml | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE, DELAYED RELEASE / ORAL | 563 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET, DELAYED RELEASE / ORAL | 103 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | CAPSULE, EXTENDED RELEASE / ORAL | 1508 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET / ORAL | 1200 mg | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | FILM / SUBLINGUAL | 4.68 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | LOTION / TOPICAL | 15 %w/w | ||
| HYDROXYPROPYL METHYLCELLULOSE E5 [II] | HYPROMELLOSE 2910 (5 MPA.S) | R75537T0T4 | TABLET / ORAL | 1200 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GNP Caldyphen | CALAMINE AND PRAMOXINE HYDROCHLORIDE | Amerisource Bergen | 515c58d7-0dc4-45e7-9155-e5270a16290e | 2026-06-04 | Warnings | 24385-072-82 24385-072 24385007282 537410b5-4125-c34f-e063-6394a90aad35 515c58d7-0dc4-45e7-9155-e5270a16290e |
Adverse event summaries are temporarily unavailable. Other product information remains available.